文献速递心脑血管急症

经皮冠状动脉介入治疗稳定型心绞痛的安慰剂对照试验

A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
PubMed 文献 · N Engl J Med · 2023-11-11
一句话结论在停用抗心绞痛药物的稳定型心绞痛且客观缺血患者中,PCI较安慰剂手术降低12周心绞痛症状评分(2.9 vs 5.6,OR 2.21,P<0.001)。

该双盲、随机、安慰剂对照试验纳入稳定型心绞痛患者,停用所有抗心绞痛药物并完成2周症状评估后,按1:1随机接受PCI或安慰剂手术,随访12周。主要终点为心绞痛症状评分(0-79分,越高越差)。301例患者中PCI组151例、安慰剂组150例;12周时平均评分PCI组2.9 vs 安慰剂组5.6(OR 2.21,95%CI 1.41-3.47,P<0.001)。安慰剂组1例因不可接受心绞痛揭盲;急性冠脉综合征PCI组4例、安慰剂组6例。结论:在接受极少或无抗心绞痛药物且有客观缺血证据的稳定型心绞痛患者中,PCI较安慰剂手术降低心绞痛症状评分,提示心绞痛相关健康状况更好。

要点

  • 停用所有抗心绞痛药物并完成2周症状评估后随机,12周时PCI组平均心绞痛症状评分2.9 vs 安慰剂组5.6(OR 2.21,95%CI 1.41-3.47,P<0.001)。
  • 症状评分0-79分,每日根据当天心绞痛发作次数、当天处方抗心绞痛药物数量及临床事件(因不可接受心绞痛或急性冠脉综合征或死亡而揭盲)计算,越高越差。
  • 靶血管中位血流储备分数0.63(IQR 0.49-0.75),中位瞬时无波形比率0.78(IQR 0.55-0.87)。
  • 安慰剂组1例因不可接受心绞痛揭盲;急性冠脉综合征PCI组4例、安慰剂组6例。
  • 缺血累及1个心脏区域242例(80%)、2个区域52例(17%)、3个区域7例(2%)。

适用人群与场景

  • 稳定型心绞痛患者,停用所有抗心绞痛药物并完成2周症状评估后随机。
  • 随机301例:PCI组151例、安慰剂组150例;平均年龄64±9岁,79%为男性。
  • 缺血累及1个心脏区域242例(80%)、2个区域52例(17%)、3个区域7例(2%)。

诊断标准与关键阈值

  • 心绞痛症状评分范围0-79分,每日根据当天心绞痛发作次数、当天处方抗心绞痛药物数量及临床事件(因不可接受心绞痛或急性冠脉综合征或死亡而揭盲)计算,分数越高表示心绞痛相关健康状况越差。

红旗征与不能漏的情况

  • 不可接受心绞痛可导致揭盲:安慰剂组1例发生不可接受心绞痛并揭盲。
  • 急性冠脉综合征:PCI组4例、安慰剂组6例。

研究设计与关键结果

  • 双盲、随机、安慰剂对照试验:稳定型心绞痛患者停用所有抗心绞痛药物,完成2周症状评估后按1:1随机接受PCI或安慰剂手术,随访12周。
  • 共301例随机:PCI组151例、安慰剂组150例;平均年龄64±9岁,79%为男性。
  • 靶血管中位血流储备分数0.63(IQR 0.49-0.75),中位瞬时无波形比率0.78(IQR 0.55-0.87)。
  • 12周随访时平均心绞痛症状评分PCI组2.9 vs 安慰剂组5.6(OR 2.21,95%CI 1.41-3.47,P<0.001)。
  • 安慰剂组1例因不可接受心绞痛揭盲;急性冠脉综合征PCI组4例、安慰剂组6例。

证据类型、等级与局限

  • 证据类型:双盲、随机、安慰剂对照试验(ORBITA-2,ClinicalTrials.gov NCT03742050)。
  • 资助:National Institute for Health and Care Research Imperial Biomedical Research Centre等。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在接受极少或无抗心绞痛药物且有客观缺血证据的稳定型心绞痛患者中,PCI较安慰剂手术降低心绞痛症状评分,提示心绞痛相关健康状况更好。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Percutaneous coronary intervention (PCI) is frequently performed to reduce the symptoms of stable angina. Whether PCI relieves angina more than a placebo procedure in patients who are not receiving antianginal medication remains unknown.

METHODS: We conducted a double-blind, randomized, placebo-controlled trial of PCI in patients with stable angina. Patients stopped all antianginal medications and underwent a 2-week symptom assessment phase before randomization. Patients were then randomly assigned in a 1:1 ratio to undergo PCI or a placebo procedure and were followed for 12 weeks. The primary end point was the angina symptom score, which was calculated daily on the basis of the number of angina episodes that occurred on a given day, the number of antianginal medications prescribed on that day, and clinical events, including the occurrence of unblinding owing to unacceptable angina or acute coronary syndrome or death. Scores range from 0 to 79, with higher scores indicating worse health status with respect to angina.

RESULTS: A total of 301 patients underwent randomization: 151 to the PCI group and 150 to the placebo group. The mean (±SD) age was 64±9 years, and 79% were men. Ischemia was present in one cardiac territory in 242 patients (80%), in two territories in 52 patients (17%), and in three territories in 7 patients (2%). In the target vessels, the median fractional flow reserve was 0.63 (interquartile range, 0.49 to 0.75), and the median instantaneous wave-free ratio was 0.78 (interquartile range, 0.55 to 0.87). At the 12-week follow-up, the mean angina symptom score was 2.9 in the PCI group and 5.6 in the placebo group (odds ratio, 2.21; 95% confidence interval, 1.41 to 3.47; P<0.001). One patient in the placebo group had unacceptable angina leading to unblinding. Acute coronary syndromes occurred in 4 patients in the PCI group and in 6 patients in the placebo group.

CONCLUSIONS: Among patients with stable angina who were receiving little or no antianginal medication and had objective evidence of ischemia, PCI resulted in a lower angina symptom score than a placebo procedure, indicating a better health status with respect to angina. (Funded by the National Institute for Health and Care Research Imperial Biomedical Research Centre and others; ORBITA-2 ClinicalTrials.gov number, NCT03742050.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Rajkumar CA, Foley MJ, Ahmed-Jushuf F, et al. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. N Engl J Med. 2023. PMID: 38015442. doi:10.1056/NEJMoa2310610

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。